CO5560534A2 - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
CO5560534A2
CO5560534A2 CO04025929A CO04025929A CO5560534A2 CO 5560534 A2 CO5560534 A2 CO 5560534A2 CO 04025929 A CO04025929 A CO 04025929A CO 04025929 A CO04025929 A CO 04025929A CO 5560534 A2 CO5560534 A2 CO 5560534A2
Authority
CO
Colombia
Prior art keywords
pharmaceutically acceptable
methanesulfonamido
quinazoline
dimethoxy
pyridyl
Prior art date
Application number
CO04025929A
Other languages
English (en)
Inventor
John Douglas Davis
Michael John Humprey
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO5560534A2 publication Critical patent/CO5560534A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Una formulación farmacéutica de liberación controlada para administración oral que comprende 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil) quinazolina, o una sal farmacéuticamente aceptable de la misma; y un adyuvante, diluyente o vehículo farmacéuticamente aceptable; caracterizada porque la formulación está adaptada para liberar al menos un 50% en peso de la 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidro-isoquinol-2-il)-5-(2-piridil)quinazolina, o la sal farmacéuticamente aceptable de la misma, después de 6 horas en el Aparato 1 descrito en la Farmacopea de Estados Unidos 24 (2000), páginas 1941-1943, que tiene recipientes de 1 litro, cestas de malla 40 (orificios de 0,4 mm), una velocidad de rotación de 100 rpm y un medio de disolución que consta de 900 mI de ácido clorhídrico 0,01 M que contiene cloruro sódico al 0,7% p/v a 37°C.2.- Una formulación de acuerdo con la reivindicación 1, en la que al menos un 30% en peso de la 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil)quinazolina, o la sal farmacéuticamente aceptable de la misma, se libera después de 3 horas.
CO04025929A 2001-10-11 2004-03-18 Formulaciones farmaceuticas CO5560534A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO5560534A2 true CO5560534A2 (es) 2005-09-30

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04025929A CO5560534A2 (es) 2001-10-11 2004-03-18 Formulaciones farmaceuticas

Country Status (32)

Country Link
EP (1) EP1434570B8 (es)
JP (1) JP4131471B2 (es)
KR (1) KR20050032510A (es)
CN (1) CN1568180A (es)
AP (1) AP2004003001A0 (es)
AR (1) AR036782A1 (es)
AT (1) ATE303135T1 (es)
BR (1) BR0213196A (es)
CA (1) CA2461168A1 (es)
CO (1) CO5560534A2 (es)
DE (1) DE60205925T2 (es)
DK (1) DK1434570T3 (es)
DO (1) DOP2002000464A (es)
EA (1) EA006168B1 (es)
ES (1) ES2246017T3 (es)
GB (1) GB0124455D0 (es)
GT (1) GT200200184A (es)
HR (1) HRP20040261A2 (es)
HU (1) HUP0600064A3 (es)
IL (1) IL160969A0 (es)
IS (1) IS7179A (es)
MA (1) MA27075A1 (es)
MX (1) MXPA04003293A (es)
NO (1) NO20041520L (es)
OA (1) OA12709A (es)
PA (1) PA8556001A1 (es)
PE (1) PE20030551A1 (es)
PL (1) PL369666A1 (es)
SV (1) SV2004001279A (es)
UY (1) UY27477A1 (es)
WO (1) WO2003032956A1 (es)
ZA (1) ZA200401976B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008526T2 (de) * 1990-07-02 1994-08-18 Bend Res Inc Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
PT1268468E (pt) * 2000-03-03 2004-01-30 Pfizer Mesilato de 4-amino-6,7dimetoxi-2- (5-metanossulfonamido-1,2,3,4-tetra-hidro-2-isoquinolil)5-5(2-piridil-quinazolina e polimorfos

Also Published As

Publication number Publication date
WO2003032956A1 (en) 2003-04-24
UY27477A1 (es) 2003-05-30
PL369666A1 (en) 2005-05-02
MA27075A1 (fr) 2004-12-20
NO20041520L (no) 2004-04-05
AR036782A1 (es) 2004-10-06
JP2005507909A (ja) 2005-03-24
PE20030551A1 (es) 2003-06-26
SV2004001279A (es) 2004-02-19
GT200200184A (es) 2003-05-23
ATE303135T1 (de) 2005-09-15
EP1434570B1 (en) 2005-08-31
IL160969A0 (en) 2004-08-31
CA2461168A1 (en) 2003-04-24
HRP20040261A2 (en) 2004-08-31
IS7179A (is) 2004-03-11
EA200400431A1 (ru) 2004-08-26
DK1434570T3 (da) 2005-11-07
DE60205925D1 (de) 2005-10-06
AP2004003001A0 (en) 2004-03-31
HUP0600064A3 (en) 2007-02-28
PA8556001A1 (es) 2003-07-28
JP4131471B2 (ja) 2008-08-13
MXPA04003293A (es) 2004-07-23
EP1434570A1 (en) 2004-07-07
HUP0600064A2 (en) 2006-06-28
CN1568180A (zh) 2005-01-19
EA006168B1 (ru) 2005-10-27
OA12709A (en) 2006-06-26
ES2246017T3 (es) 2006-02-01
BR0213196A (pt) 2004-08-31
ZA200401976B (en) 2004-07-12
KR20050032510A (ko) 2005-04-07
GB0124455D0 (en) 2001-12-05
DOP2002000464A (es) 2003-04-15
DE60205925T2 (de) 2006-06-08
EP1434570B8 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
DE60232496D1 (de) Tabletten, die in der mundhöhle schnell zerfallen
WO2005065646A3 (en) Novel drug compositions and dosage forms
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
RU2016122609A (ru) Составы соединений азаиндола
DK1435909T3 (da) Stabil sammensætning indeholdende partikler i en frossen vandig matrix
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
PE20021017A1 (es) Composicion parenteral reconstituible
CO5280073A1 (es) Composiciones
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
ATE213940T1 (de) Parenteral anzuwendende arzneizubereitung enthaltend amiodaron
MA27980A1 (fr) Nouvelle composition
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
CO5560534A2 (es) Formulaciones farmaceuticas
AR032614A1 (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
RU2008103549A (ru) Применение активаторов растворимой гуанилат-циклазы для лечения нарушений кровоснабжения
ECSP045045A (es) Formulaciones farmacéuticas de liberación controlada que comprende 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil)quinazolina
DE60217903D1 (de) Flüssige pharmazeutische zusammensetzungen auf wasserbasis in suspensionsform zur oralen verabreichung von ibuprofen
MA26788A1 (fr) COMPOSITIONS PHARMACEUTIQUES DESTINÉES à L'ADMINISTRATION PAR VOIE ORALE DE PHLOROGLUCINOL ET LEUR PRÉPARATION
CO5170463A1 (es) Formas polimorfas de un citrato de azobiciclo [2,2,2]octan- 3-amina y sus composiciones farmaceuticas
ATE302010T1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
AR054377A1 (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) (4-piridilmetil) ftalazin -1-il0) micronizado y sus sales
PE20050086A1 (es) Combinacion farmaceutica que comprende eletriptan o una sal farmaceuticamente aceptable y bicarbonato de sodio

Legal Events

Date Code Title Description
FC Application refused